Browse 1+ research peptides. Filter by category or search by name.
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks. Currently in Phase 3 development.